

Version 1.0.3

Submission[Home](#) > [Submission](#)

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/04/2016
Deadline Date	29/04/2016
Date Submitted	27/04/2016
Type	Historic Performance in Initiating
NHS provider	Maldstone and Tunbridge Wells NHS Trust

Showing records 1 to 25 of 33.

Pages: [1](#) [2](#) [Next](#) >

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirm Status
78606	14/EM/0172	142310	NHS Permission	BABY OSCAR- Outcome after Selective early Treatment for Closure of patient Ductus Arteriosus in Pre-term babies.	13/10/2015	12/02/2016	No	122							No						Please Select...
78607	10/H/1313/2	21860	NHS Permission	LuCID: Longitudinal European Clostridium difficile Infection Diagnosis	27/08/2015	11/09/2015	No	15							No						Please Select...
78608	15/WM/0457	195511	NHS Permission	DARATUMUMAB: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteas	02/03/2016	10/03/2016	Yes	22/03/2016	8	12	20				Yes						Please Select...
78609	15/LO/1807	187302	NHS Permission	Checkmate 331 An Open-Label, Randomized, Phase 3 Study of Nivolumab or chemotherapy in subjects with	25/01/2016	23/02/2016	No	29							Within 70 Days						Please Select...

78615	14/WM/1055	152229	NHS Permission	AB12006 - A prospective, multicentre, randomised, double blind, placebo-controlled, 2-parallel group, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in com	10/07/2015	23/07/2015	Yes	01/12/2015	13	131	144							No				Please Select...
78616	14/LO/1043	137864	NHS Permission	LEAVO - A multicentre Phase 111 Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of Intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema	15/05/2015	18/06/2015	Yes	01/10/2015	34	105	139							No				Please Select...
78617	15/EM/0344	183906	NHS Permission	MORAb-099-201 A randomised, double-blind, place-controlled study of the safety and efficacy of amatumumab in combination with pertuzumab and cisplatin in subjects with unresectable malignant pleural mesothelioma	14/03/2016	23/03/2016	No		9									Within 70 Days				Please Select...
78618	15/LO/0016	164539	NHS Permission	MONARCH 3: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2335219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with	29/04/2015	28/05/2015	No		29									No				Please Select...

